Biotronik is set to showcase its magnetic resonance imaging (MRI) approved implantable heart failure devices at the European Society of Cardiology congress, being held between 25-29 August 2012.
The MRI-approved devices include Lumax 740 HF-T CRT defibrillator (CRT-D) and Evia HF-T CRT pacemaker (CRT-P), which utilizes the company’s ProMRI technology.
The company said that both devices possess Heart Failure Monitor that enables continuous, advanced heart failure monitoring, and form part of ProMRI portfolio that includes the Lumax 740 ICDs, Evia and Estella pacemakers and compatible leads.
German University of Wurzburg cardiologist professor Dr. Wolfgang Bauer said heart failure patients tend to be older, aged 65 years or older, with more comorbidities.
"There is a clear advantage when using a device such as the Evia HF-T or Lumax 740, which will enable physicians not only to monitor the patient remotely but also enable them to have MR scans — a likely occurrence in heart failure patient populations," Bauer added.
Commenting on the display Biotronik president Christoph Böhmer said, "BIOTRONIK’s CRT portfolio includes cutting-edge technologies such as ProMRI and the BIOTRONIK Heart Failure Monitor that enable physicians to choose the optimum combination for each patient and indication, and BIOTRONIK invests in landmark trials such as the EchoCRT trial to identify and answer open questions in the heart failure population and pave the way for continued clinical excellence."